Insurance Coverage Update: Social media users noted CVS Caremark's decision to restore coverage for Eli Lilly's Zepbound, reversing a prior preference for Novo Nordisk's Wegovy. This shift follows legal challenges and public pushback. Observers highlighted potential effects on market share in the obesity treatment space.
Competitor Comparison: Discussions compared Novo Nordisk's performance against Eli Lilly, pointing to the latter's stronger gains in recent years. Some posts referenced revenue growth figures and product pipelines. Analysts on the platform emphasized ongoing rivalry in the GLP-1 sector.
Broader Sentiment: Overall commentary reflected cautious views amid these developments, with focus on how such changes might influence investor perceptions. Participants discussed the competitive landscape without endorsing specific positions.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Revenue
Novo Nordisk had revenues of $15B in Q1 2026.
You can track NVO financials on Quiver Quantitative's NVO stock page.
You can access data on NVO stock through the Quiver Quantitative API.
Novo Nordisk Hedge Fund Activity
We have seen 569 institutional investors add shares of Novo Nordisk stock to their portfolio, and 901 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX added 19,333,750 shares (+inf%) to their portfolio in Q1 2026, for an estimated $693,211,606
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 9,884,077 shares (+808.8%) to their portfolio in Q1 2026, for an estimated $354,393,580
- FMR LLC removed 8,664,705 shares (-86.5%) from their portfolio in Q1 2026, for an estimated $310,672,997
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 7,827,491 shares (+inf%) to their portfolio in Q1 2026, for an estimated $280,654,689
- TWO SIGMA INVESTMENTS, LP added 5,943,310 shares (+1731.8%) to their portfolio in Q1 2026, for an estimated $213,097,380
- GOLDMAN SACHS GROUP INC removed 5,865,741 shares (-53.4%) from their portfolio in Q1 2026, for an estimated $210,316,143
- BOSTON PARTNERS removed 5,231,804 shares (-97.3%) from their portfolio in Q1 2026, for an estimated $187,586,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $57.25.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
